Today: 7 February 2026
Subscribe
Browse Category

Mergers and Acquisitions News 6 January 2026 - 14 January 2026

Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue shares rose 0.4% to $17.08 in mid-morning trading after Kimberly-Clark filed new deal documents with U.S. regulators. The stock remains about 5% below the value implied by the pending cash-and-stock takeover. Kenvue shareholders are set to vote on the deal Jan. 29. The transaction’s value fluctuates with Kimberly-Clark’s share price.
14 January 2026
···
Netflix stock slips as all-cash Warner Bros bid talk swirls, with earnings days away

Netflix stock slips as all-cash Warner Bros bid talk swirls, with earnings days away

Netflix shares fell 1.6% Wednesday as investors weighed reports it may switch to an all-cash bid for Warner Bros Discovery’s studio and streaming assets, valued at $82.7 billion. Paramount Skydance, offering $108.4 billion for all of Warner Bros, escalated its challenge with a lawsuit and board nominations. Warner Bros dismissed the lawsuit as meritless. Netflix’s quarterly results are due January 20.
14 January 2026
····
Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol shares rose 2.2% to $148.28 Tuesday, bucking a broader market decline after finalizing its $10.5 billion acquisition of CommScope’s CCS business. Analysts at Barclays, Citi, and Truist raised price targets, citing expected sales growth and stronger demand. The company projects CCS will add $4.1 billion in 2026 sales and $0.15 to EPS, excluding costs. Quarterly earnings are due Jan. 28.
13 January 2026
···
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

New York, Jan 9, 2026, 20:01 (EST) — Market closed. Merck & Co (MRK.N) shares slipped on Friday following reports that the pharma giant is in talks to acquire cancer-focused biotech Revolution Medicines (RVMD.O) for as much as $32 billion. Merck ended the day down 0.4% at $110.53, after swinging between $110.26 and $112.46. (Reuters) The possible bid comes as Merck looks to bolster its oncology portfolio ahead of patent cliffs on its blockbuster Keytruda later this decade. Such a deal would arrive amid investor pressure on big pharma to weigh pipeline investments against buybacks and dividends, especially with interest
10 January 2026
····
D-Wave Quantum stock (QBTS) slides after $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum stock (QBTS) slides after $550 million Quantum Circuits deal puts dilution in focus

New York, January 7, 2026, 20:16 (EST) — Market closed D-Wave Quantum shares fell 3.4% to close at $30.20 on Wednesday after the quantum computing company announced a $550 million deal for Quantum Circuits. StockAnalysis The move matters now because D-Wave is trying to widen its pitch beyond quantum annealing — a specialised method used mainly for optimisation problems such as scheduling — and push harder into “gate-model” systems, the general-purpose approach most labs pursue. Gate-model machines run sequences of operations on qubits, the basic unit of quantum information. The deal followed a separate announcement on Tuesday in which D-Wave
8 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

New York, Jan 7, 2026, 15:40 (EST) — Regular session Merck & Co (MRK.N) shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics (CDTX.O) and expected to finish the acquisition through a merger later in the day. The company said the deal will be treated as an asset acquisition, lifting 2026 research and development expense by about $9.0 billion and cutting earnings per share by roughly 30 cents in the first 12 months. “The acquisition of Cidara strengthens and complements our expanding respiratory
7 January 2026
·····
Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

New York, Jan 7, 2026, 05:03 EST — Premarket Ventyx Biosciences shares jumped about 66% before the bell on Wednesday after a report that Eli Lilly is in advanced talks to buy the biotech company for more than $1 billion. The stock traded at $16.70 in premarket action, versus a $10.05 regular-session close. Public The move matters because a confirmed deal would lock in a takeover premium for a company whose value has swung sharply on trial timelines and pipeline expectations. It also tests whether big drugmakers are willing to pay up for clinical-stage assets tied to inflammation and obesity-linked
7 January 2026
···
Gold.com stock steadies as Monex deal closes and gold prices hit a one-week high

Gold.com stock steadies as Monex deal closes and gold prices hit a one-week high

New York, Jan 6, 2026, 10:06 EST — Regular session Gold.com Inc shares were little changed on Tuesday, up less than 0.1% at $36.35 in early U.S. trading, after the precious-metals dealer confirmed it had closed its acquisition of Monex Precious Metals. The deal lands as gold prices regain momentum, a backdrop that can lift volumes for retailers and traders that make money on buying and selling bullion, coins and storage services. Gold.com has been building out that direct-to-consumer model as investors look for hedges against geopolitical risk and shifting U.S. rate expectations. Spot gold rose 0.4% to $4,463.63 an
6 January 2026
··
US stock market: Vistra stock pops in premarket on $4.7B Cogentrix deal amid AI power-demand boom

US stock market: Vistra stock pops in premarket on $4.7B Cogentrix deal amid AI power-demand boom

New York, January 6, 2026, 06:10 EST — Premarket Vistra shares were up 4.4% at $170.17 in premarket trading on Tuesday after the U.S. power producer said it would buy Cogentrix Energy from Quantum Capital Group in a deal valued at about $4.7 billion. TradingView+1 The purchase lands as investors sharpen their focus on electricity supply, with data centers racing to support artificial intelligence workloads pushing demand higher across the U.S. grid. The Energy Information Administration has forecast U.S. power consumption will hit record highs in 2026. Reuters For Vistra, the deal is another bet that owning dispatchable generation —
6 January 2026
···
BlueScope Steel stock jumps 21% on A$30 takeover bid — the next catalyst investors are watching

BlueScope Steel stock jumps 21% on A$30 takeover bid — the next catalyst investors are watching

SYDNEY, Jan 6, 2026, 16:58 AEDT — Market closed BlueScope Steel Limited (ASX:BSL) shares closed up 20.57% at A$29.48 on Tuesday after Australian conglomerate SGH and U.S. steelmaker Steel Dynamics confirmed an approach to buy the company for A$30 a share in cash. Investing.com+1 The move pulled the stock to within about 1.7% of the indicative price, leaving traders to price the risk that talks fail — and the chance the bidders lift their offer. The last close before the rally was A$24.45. Investing.com+1 The timing matters because BlueScope has been arguing its cash flow and earnings power are set
6 January 2026
···
1 2 3 4 … 10

Stock Market Today

Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next

Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next

7 February 2026
Stellantis shares plunged 23.7% to $7.28 Friday after the company disclosed about €22.2 billion in charges tied to a reset of its electric-vehicle strategy and said it will skip its 2026 dividend. The automaker flagged a preliminary net loss of €19–21 billion for the second half of 2025. Shares rose 1.6% in late after-hours trading. Investors await Feb. 26 results and a May 21 Investor Day.
Intel stock jumps on China server CPU delays as traders map the week ahead

Intel stock jumps on China server CPU delays as traders map the week ahead

7 February 2026
Intel shares rose 4.87% to $50.59 Friday, trailing gains by Nvidia and Broadcom as chip stocks rallied. Sources said Intel and AMD warned Chinese customers of longer waits and higher prices for some server CPUs, with Intel lead times reaching six months. Intel said China accounts for over 20% of its revenue. Investors await key U.S. jobs and inflation data next week.
IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

7 February 2026
IRS staffing has dropped to 2021 levels as the 2026 tax filing season begins, according to a Treasury watchdog. The agency faces a backlog of about 2 million returns, 129% above pre-pandemic levels. Most e-filers using direct deposit still get refunds within 21 days, but paper filings and amended returns could see delays. The IRS lowered its call-answer target to 70% for this season.
Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

7 February 2026
Plug Power shares rose 11.6% Friday to $2.08 after a sharp drop the previous day, as attention shifted to a Feb. 17 shareholder vote on expanding authorized shares. The company failed to secure enough votes earlier this week and is urging overseas holders to participate. CEO Andy Marsh cited difficulties for European investors in casting ballots. A reverse stock split remains possible if the proposal fails.
Go toTop